ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Sonoma Pharmaceuticals, Inc. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -3.39% over the last 5 years
2
The company has declared Positive results for the last 3 consecutive quarters
- NET PROFIT(HY) Higher at USD -1.4 MM
- INVENTORY TURNOVER RATIO(HY) Highest at 3.69 times
- DEBTORS TURNOVER RATIO(HY) Highest at 8.21 times
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -59.65%, its profits have risen by 10.1%
4
Increasing Participation by Institutional Investors
- Institutional investors have increased their stake by 1.04% over the previous quarter and collectively hold 10.4% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
5
Below par performance in long term as well as near term
- Along with generating -59.65% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Sonoma Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Sonoma Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Sonoma Pharmaceuticals, Inc.
-59.65%
-0.68
106.14%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-3.39%
EBIT Growth (5y)
3.42%
EBIT to Interest (avg)
-4.46
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.16
Sales to Capital Employed (avg)
2.91
Tax Ratio
18.92%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
9.36%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.07
EV to EBIT
-0.46
EV to EBITDA
-0.48
EV to Capital Employed
1.25
EV to Sales
0.07
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-271.98%
ROE (Latest)
-98.19%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend15What is working for the Company
NET PROFIT(HY)
Higher at USD -1.4 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 3.69 times
DEBTORS TURNOVER RATIO(HY)
Highest at 8.21 times
NET SALES(Q)
At USD 5.56 MM has Grown at 25.52%
PRE-TAX PROFIT(Q)
Highest at USD -0.5 MM
-5What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -3.94 MM
ROCE(HY)
Lowest at -84.6%
CASH AND EQV(HY)
Lowest at USD 4.96 MM
Here's what is working for Sonoma Pharmaceuticals, Inc.
Net Profit
Higher at USD -1.4 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Inventory Turnover Ratio
Highest at 3.69 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 8.21 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Net Sales
At USD 5.56 MM has Grown at 25.52%
over average net sales of the previous four periods of USD 4.43 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Pre-Tax Profit
Highest at USD -0.5 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD -0.5 MM has Grown at 42.38%
over average net sales of the previous four periods of USD -0.86 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Here's what is not working for Sonoma Pharmaceuticals, Inc.
Operating Cash Flow
Lowest at USD -3.94 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Cash and Eqv
Lowest at USD 4.96 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
